Correlation of CYP2C19 Genetic Polymorphisms With Helicobacter pylori Eradication in Patients With Cirrhosis and Peptic Ulcer

Journal of the Chinese Medical Association

Volumn 73, Issue 4, 2010, Pages 188-193

  Lay, Chii Shyan ^a   Lin, Jiun Rong ^b  

^a LIN SHIN HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

cirrhosis; CYP2C19; Helicobacter pylori eradication; peptic ulcer

Indexed keywords

AMOXICILLIN; BACTERIAL DNA; CLARITHROMYCIN; CYTOCHROME P450 2C19; RABEPRAZOLE; UREASE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DUODENUM ULCER; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STOMACH ULCER; ULCER HEALING; UREA BREATH TEST;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AMOXICILLIN; ARYL HYDROCARBON HYDROXYLASES; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PEPTIC ULCER; POLYMORPHISM, GENETIC;

EID: 77951771718     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/S1726-4901(10)70039-3     Document Type: Article

References (35)

1. Wong B., Lam S.K., Wang W.W., Chen J.S., Zheng T.T., Feng R.E., Lai K.C., et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China. A randomized controlled trial. JAMA 291 (2004) 187-194
2. Goodwin C.S., Mendall M.M., and Northfield T.C. Helicobacter pylori infection. Lancet 349 (1997) 265-309
3. Ofman J.J., Etchason J., Fullerton S., Kahn K.L., and Soll A.H. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences. Ann Intern Med 126 (1997) 280-291
4. Moayyedi P., Chalmers D.M., and Axon A. Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. J Gastroenterol 32 (1997) 24-27
5. Furuta T., Ohashi K., Kamata T., Takashima M., Kosuge K., Kawasaki T., Hanai H., et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 129 (1998) 1027-1030
6. Chen C.T., Wang T.F., Chan C.C., Lee F.Y., Chang F.Y., Lin H.C., Hou M.C., et al. Role of chronic Helicobacter pylori infection in hyperdynamic circulation of cirrhotic patients. Hepatogastroenterology 49 (2002) 208-212
7. Wang C.H., Ma L.R., Lin R.C., Kuo J.Y., and Chang K.K. Helicobacter pylori infection and risk of peptic ulcer among cirrhotic patients. J Formos Med Assoc 96 (1997) 55-58
8. Lay C.S., Tsai Y.T., Teg C.Y., Shyu W.S., Guo W.S., Wu K.L., and Lo K.J. Endoscopic variceal ligation in prophylaxis of first variceal bleeding in cirrhotic patients with high-risk esophageal varices. Hepatology 25 (1997) 1346-1350
9. Zullo A., Rinaldi V., Meddi P., Folino S., Lauria V., Diana F., Winn S., et al. Helicobacter pylori infection in dyspeptic cirrhotic patients. Hepatogastroenterology 46 (1999) 395-400
10. Vergara M., Calvet X., and Roque M. Helicobacter pylori is a risk factor for peptic ulcer disease in cirrhotic patients. A meta-analysis. Eur J Gastroenterol Hepatol 14 (2002) 717-722
11. Basset C., Holton J., Gatta L., Ricci C., Bernabucci V., Liuzzi G., and Vaira D. Helicobacter pylori infection: anything new should we know?. Aliment Pharmacol Ther 20 Suppl (2004) 31-41
12. 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy. World J Gastroenterol 11 (2005) 1680-1684
13. Cederbrant G., Kahlmeter G., and Ljungh A. Proposed mechanism for metronidazole resistance in Helicobacter pylori. J Antimicrob Chemother 29 (1992) 115-120
14. Sapone A., Vaira D., Trespidi S., Perna F., Gatta L., Tampieri A., Ricci C., et al. The clinical role of cytochrome P450 genotypes in Helicobacter pylori management. Am J Gastroenterol 98 (2003) 1010-1015
15. Take S., Mizuno M., Ishiki K., Nagahara Y., Yoshida T., Inaba T., Yamamoto K., et al. Interleukin 1β genetic polymorphism influences the effect of cytochrome P2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. Am J Gastroenterol 98 (2003) 2403-2408
16. Richardson P., Hawkey C.J., and Stack W.A. Proton pump inhibitors: pharmacology and rationale for use in gastrointestinal disorders. Drugs 56 (1998) 307-335
17. Gardner J.D., Perdomo C., Sloan S., Hahne W.F., Barth J.A., Rodriguez S.S., and Robinson M. Integrated acidity and rabeprazole pharmacology. Aliment Pharmacol Ther 16 (2002) 455-464
18. Furuta T., Kaneko E., Suzuki M., Arai H., and Futami H. Quantitative study of Helicobacter pylori in gastric mucus by competitive PCR using synthetic DNA fragments. J Clin Microbiol 34 (1996) 2421-2425
19. de Morais S.M.F., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., and Goldstein J.A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269 (1994) 15419-15422
20. de Morais S.M.F., Wilkinson G.R., Blaisdell J., Meyer U.A., Nakamura K., and Goldstein J.A. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46 (1994) 594-598
21. Kubota T., Chiba K., and Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60 (1996) 661-666
22. Ishizaki T., and Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 13 Suppl (1999) 27-36
23. Sohn D.R., Kobayashi K., Chiba K., Lee K.H., Shin S.G., and Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 262 (1992) 1195-1202
24. Ieiri I., Kubota T., Urae A., Kimura M., Wada Y., and Mamiya K. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 59 (1996) 647-653
25. Yamada S., Onda M., Kato S., Matsuda N., Matsuhisa T., Yamada N., Miki M., et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J Gastroenterol 36 (2001) 669-672
26. Schulz K.F., and Grimes D.A. Sample size calculations in randomized trials: mandatory and mystical. Lancet 365 (2005) 1348-1353
27. Lo G.H., Yu H.C., Chan Y.C., Chen W.C., Hsu P.I., Lin C.K., and Lai K.H. The effects of eradication of Helicobacter pylori on the recurrence of duodenal ulcers in patients with cirrhosis. Gastrointest Endosc 62 (2005) 350-356
28. Wu C.S., Lin C.Y., and Liaw Y.F. Helicobacter pylori in cirrhotic patients with peptic ulcer disease: a prospective, case controlled study. Gastrointest Endosc 42 (1995) 424-427
29. Giannini E., Fasoli A., Botta F., Romagnoli P., Malfatti F., Chiarbonello B., Mamone M., et al. Helicobacter pylori infection is associated with greater impairment of cytochrome P-450 liver metabolic activity in anti-HCV positive cirrhotic patients. Dig Dis Sci 48 (2003) 802-808
30. Villalan R., Maroju N.K., Kate V., and Ananthakrishnan N. Is Helicobacter pylori eradication indicated in cirrhotic patients with peptic ulcer disease?. Trop Gastroenterol 27 (2006) 166-168
31. Wang C.H., Ma L.R., Lin R.C., Kuo J.Y., and Chang K.K. Helicobacter pylori infection and risk of peptic ulcer among cirrhotic patients. J Formos Med Assoc 96 (1997) 55-58
32. Lodato F., Azzaroli F., Di Girolamo M., Feletti V., Cecinato P., Lisotti A., Festi D., et al. Proton pump inhibitors in cirrhosis: tradition or evidence-based practice?. World J Gastroenterol 21 (2008) 2980-2985
33. Miyaji H., Ito S., Azuma T., Ito Y., Yamazaki Y., Ohtaki Y., Sato F., et al. Effects of Helicobacter pylori eradication therapy on hyper-ammonaemia in patients with liver cirrhosis. Gut 40 (1997) 726-730
34. Siringo S., Vaira D., Menegatti M., Piscaglia F., Sofia S., Gaetani M., Miglioli M., et al. High prevalence of Helicobacter pylori in liver cirrhosis: relationship with clinical and endoscopic features and the risk of peptic ulcer. Dig Dis Sci 42 (1997) 2024-2030
35. Lay C.S., Lai Y.L., and Lin J.R. Effect of omeprazole in one patient with peptic ulcer. Mid Taiwan J Med 10 (2005) 107-111